Drug induced lupus

1. Hoffman BJ. Sensitivity tu sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syphilol 1945; 51: 190–192.

2. Mansilla-Tinoco R, Harland SJ, Ryan PJ, et al. Hydralazin, antinuclear antibodies, and the lupus syndrome. Br Med J 1984; 289: 410–412.

3. Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA DR and sex on susceptibility. Lancet 1980; 1: 1107–1109.

4. Gunnarsson I, Nordmark B, Hassan Bakri A, Grondal G, et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment – the role of IL-10 and HLA. Rheumatology 2000; 39(8): 886–893.

5. Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-2B with symptomatic procainamideinduced lupus. N Engl J Med 1988; 318: 1431–1436.

6. Fenniche S, Dhaoui A, Ammar FB, Benmously R, Marrak H, Mokhtar I. Acebutolol-induced subacute cutaneous lupus erythematosus. Skin Pharmacol Physiol 2005; 18: 230–233.

7. Spiera RF, Berman RS, Werner AJ, Spiera H. Ticlopidine-induced lupus: A report of 4 cases. Arch Intern Med 2002; 162: 2240–2243.

8. Capponi A, De Simone C, Guerriero C, Rotoli M, Bartoloni C. Ro/SSA-positive cutaneous lupus induced by carbamazepine. Arch Dermatol 2005; 141: 103–104.

9. Petri M, Albritton J. Antibiotic allergy in systemic lupus erythematosus. J Rheumatol 1192; 19: 265–269.

10. Elkayam O, YaronM, Caspi D. Minocycline – induced autoimmune syndromes: on overview. Semin Arth Rheum 1999; 28: 392–397.

11. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autommune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J 1996; 312: 169–172.

12. Bonsmann G, Schiller M, Luger TA, et al. Terbinafine- incuced subacute cutaneous lupus erythematosus. Arch Dermatol 2001; 44: 925–931.

13. Petri M, Kim MY, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.

14. Buyon JP, Petri M, Kim MY, et al. The effect of combined estrogenprogesteron hormon replacement therapy on disease akti-vity in systemic lupus erythematosus: a randomized trial. Ann Int Med 2005; 142: 953–961.

15. Khattak FH, Morris IMM, Mattingly PC. Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. Br J Rheumatol 1993; 22: 104–104.

16. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon – alpha in lupus psychosis. Arthritis Rheum 1992; 35: 417–422.

17. Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferfon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70–74.

18. Vasoo S. Drug induced lupus: an update. Lupus 2006; 15(11): 757–761.

19. Siddiqui MA, Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther 2002; 9: 163–165.

20. Jolles S, Sewell WA, Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf 2000; 22: 215–216.

21. Graziadei IW, Obermoser GE, Sepp NT, Erkhart KH, Vogel W. Druginduced lupus like syndrome associated with severe autoimmune hepatitis. Lupus 2003; 12: 409–412.

22. Batchelor JR, Welsh KI, Tinico RM, Dollery CT, Hughes GRV, et al. Hydralazine-induced systemic lupus erhythematosus: influence of HLA-D and sex o susceptibility. Lancet 1980; 315: 1107–1109.

23. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erthematosus. Arthritis Rheum 1997; 40: 1725.

25. Aringer M. EULAR/ACR classification criteria for SLE. Semin Athritis Rheum. 2019; 49(3S): S14–17.

26. Fritzler MJ, Tan EM. Antibodies to Histones in Drug-Induced and Idiopathic Lupus Erythematosus. J Clin Invest 1978; 62(3): 560–567.

27. Rubert LR. Drug – induced lupus. J Tox 2005; 209(2): 135–147.

28. Dostál C, Vencovský J. Léky indukovaný lupus erythematodes. Systémový lupus erythemadoes. Cheb: Medprint 1997; 110–112.

29. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatol 2009; 48: 716–720.

30. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusion of anti.tumour necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid artrhritis. Arthritis Rheum 1998; 41: 1552–1563.

31. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear anti-bodies following infliximab treatment in patients with rheumatoid arthritis or spondylartrhropathy. Arthritis Rheum 2003; 48: 1015–1023.

32. Vermiere S, Norman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 2003; 125: 32–39.

33. Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008; 28: 445–455.

34. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor α agents. Sem Arthr and Rheum 2008; 37: 381–387.

35. Caramaschi P, Biasi D, Colombatti M, et al. Anti-TNF-α therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006; 26: 209–214.

36. Takase K, Horton SC, Ganesha A, Das S, McHugh A, Emery P, et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis 2014; 9: 1695–1699.

37. de Bandt M, Sibilia J, Loët XL, Prouzeau S, Fautrel B, Marcelli Ch, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthr Res Ther 2005; 7: 545–551.

38. Thornhill J, Watson KD, Lord PA, Symmons DP, Hyrich KL. Drug-induced lupus inn patients wiht inflammatory artrhitis treated with TNF blocking agents: results from the BSR Biologics Register. BSR Abstracts 2008.

39. Asami Y, Ishiguro H, Ueda A, Nakajima H. First report of membranous nephropathy and systemic lupus erthymetosus associated with abatacept in rheumatoid arthritis. Clin Exp Rheumatol 2016; 34(6): 1122.

40. Tarazi M, Aiempanakit K, Werth VP. Subacute cutaneous lupus erythematosus and systemic lupus erthematosus associated with abatacept. JAAD Case Rep 2018; 4(7): 698–700.

41. Lorenz HM, Herrrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 2000; 5: 443–449.

42. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001; 167: 6821–6826.

43. Ferracioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002; 61: 358–361.

44. Bertsias GK, Tektonidou M, Amoura Z, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Commitee for International Clinical Studies Including Theurapeutics. Ann Rheum Dis 2008; 67: 195–205.